— Seattle biotech company OncoResponse landed $27 million to advance the development and testing of its antibody-based immunotherapy treatments that fight cancer.

  • New funds will support the development of OR502 and OR2805, immunotherapy candidates undergoing testing.
  • OncoResponse, founded in 2016, is led by CEO and founder Clifford Stocks. He previously led Theraclone Sciences and was a longtime exec at Cialis-maker ICOS Corporation, which Eli Lilly acquired for $2.3 billion in 2007.
  • The company raised $40 million 2018, followed by an additional $40 million in 2021.
  • The funds consist of a $13 million grant from the Cancer Prevention and Research Institute of Texas, as well as $14 million from existing investors. The round was led by RiverVest Venture Partners, with participation from ARCH Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, InterVest, and others.
Like what you're reading? Subscribe to GeekWire's free newsletters to catch every headline

Job Listings on GeekWork

Find more jobs on GeekWork. Employers, post a job here.